ArticleAnnals of hematology2025

Treatment outcomes in elderly patients ≥ 65 years with Large B-Cell Lymphoma (LBCL): a real-world single center experience focusing on potential CD19-CAR-T eligibility in second line.

Elena Maiolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.